[Megaloblastic anemia: rapid and economical study]

Area of Science:

• Clinical Biochemistry
• Hematology

Background:

• Megaloblastic anemias result from cobalamin (vitamin B12) or folate deficiency.
• Current diagnostic methods, like vitamin level assays, are expensive and not always definitive.
• There is a need for cost-effective and accurate differential diagnostic tools.

Purpose of the Study:

• To evaluate the diagnostic utility of homocysteine (HC), methylmalonic acid (MMA), and formiminoglutamic acid (FIGLU) tests in differentiating cobalamin and folate deficiencies.
• To compare the cost-effectiveness of these biochemical markers against standard vitamin level testing.

Main Methods:

• Sixty-two patients with suspected megaloblastic anemia underwent simultaneous testing for HC, MMA, and FIGLU.
• A therapeutic trial involving vitamin B12 and folic acid administration was used as a diagnostic benchmark.
• Reticulocyte counts were monitored to assess treatment response.

Main Results:

• The MMA test demonstrated 97.9% specificity for cobalamin deficiency.
• The HC test showed low specificity (4.2%) alone but increased to 91.6% when combined with a negative FIGLU test.
• The FIGLU test exhibited high specificity (92.3%) for folate deficiency.
• The biochemical marker tests were found to be 11 times less expensive than vitamin level assays.

Conclusions:

• MMA and FIGLU tests, particularly when used in combination with HC, provide a highly specific and cost-effective method for differentiating cobalamin and folate deficiencies.
• These biochemical markers represent a valuable diagnostic strategy for megaloblastic anemias, offering significant cost savings.